Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Generic Drug Manufacturer Inspections Under OIG Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA notes its efforts to beef up foreign inspections in GDUFA performance report to Congress.


Related Content

FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
Culture Clash: FDA Tries to Re-Educate Indian Firms on Processes and Accurate Reporting
FDA Quality Profiling: Agency Hopes to Channel Corporate Attention (And Money) To Quality Systems


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts